Pharvaris NV (PHVS)
20.66
+0.31
(+1.52%)
USD |
NASDAQ |
May 20, 16:00
Pharvaris Shareholders Equity (Quarterly): 387.87M for March 31, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 387.87M |
| December 31, 2023 | 424.53M |
| September 30, 2023 | 162.09M |
| June 30, 2023 | 188.80M |
| March 31, 2023 | 140.83M |
| December 31, 2022 | 160.07M |
| September 30, 2022 | 182.00M |
| June 30, 2022 | 199.07M |
| Date | Value |
|---|---|
| March 31, 2022 | 213.06M |
| December 31, 2021 | 232.05M |
| September 30, 2021 | 249.87M |
| June 30, 2021 | 264.46M |
| March 31, 2021 | 276.16M |
| December 31, 2020 | 117.81M |
| September 30, 2020 | 45.42M |
| December 31, 2019 | 20.92M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
20.92M
Minimum
Dec 2019
424.53M
Maximum
Dec 2023
204.06M
Average
193.94M
Median
Shareholders Equity (Quarterly) Benchmarks
| uniQure NV | 146.75M |
| ProQR Therapeutics NV | 37.60M |
| Merus NV | 349.45M |
| argenx SE | -- |
| Pharming Group | 205.94M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 407.77M |
| Total Liabilities (Quarterly) | 19.90M |